-
Mashup Score: 5
SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
In February, the Ministry of Health, Labour, and Welfare in Japan approved epcoritamab for the treatment of patients with relapsed or refractory follicular lymphoma. #lymsm #hematology https://t.co/2H0pkzaU8l
-
-
Mashup Score: 6
Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The combination of tambiciclib and zanubrutinib generated responses in patients with relapsed/refractory #DLBCL, according to data from a phase 2a trial conducted in China. #hematology #lymsm https://t.co/WLESjwkX8d https://t.co/l0WHoo27si
-
-
Mashup Score: 3
The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer in February. #FDA #pcsm https://t.co/MaK0Oks01M
-
-
Mashup Score: 4FDA Grants Breakthrough Therapy Designation to Petosemtamab Plus Pembrolizumab for PD-L1+ HNSCC - 5 day(s) ago
Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has granted breakthrough therapy designation to petosemtamab plus pembrolizumab for the first-line treatment of adult patients with recurrent or metastatic HNSCC with a PD-L1 combined positive score of at least 1. #hncsm #FDA https://t.co/rtNPO5VlGC https://t.co/XQ7SKgufro
-
-
Mashup Score: 4
The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @NCCN Guidelines for metastatic uveal #melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease. #oncology https://t.co/S7MpOOaQjh
-
-
Mashup Score: 2
The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has granted priority review to the new drug application seeking the approval of zongertinib for the treatment of adult patients with unresectable or metastatic NSCLC harboring HER2 mutations who have received prior systemic therapy. #lcsm https://t.co/sIVieox0jD https://t.co/Jw4HdHsrgH
-
-
Mashup Score: 5Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases - 5 day(s) ago
R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Survey respondents indicated that select patients with bone loss of no more than 75% and no less than 25% would be eligible to undergo either resection and endoprosthetic reconstruction or internal fixation. @RLRandallMD @UCD_Cancer Read here: https://t.co/LodWTnM1Uu
-
-
Mashup Score: 5
The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has accepted and granted priority review to a new drug application seeking accelerated approval of the novel, small molecule imipridone dordaviprone for the treatment of patients with recurrent H3K27M-mutant diffuse glioma. #FDA #glioma https://t.co/4whWLGTDSS https://t.co/zwn3LQ58H8
-
-
Mashup Score: 2Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer - 5 day(s) ago
Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Leading gynecologic oncologists @AngelesSecord, @DrDanaChase, @BPothuri, @DrPremalThaker, and Thomas Krivak, MD—delve into frontline maintenance strategies for advanced ovarian cancer. 🎥 Watch the full discussion here: https://t.co/UwF7VarcF9
-
SIGX1094 won a fast track designation by the @US_FDA for use in patients with diffuse gastric cancer. #stcsm #FDA https://t.co/yX1nsM6SI1 https://t.co/8vs4nx4yBn